These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24101450)

  • 1. Defining high risk: cost-effectiveness of extended-duration thromboprophylaxis following major oncologic abdominal surgery.
    Iannuzzi JC; Rickles AS; Kelly KN; Fleming FJ; Dolan JG; Monson JR; Noyes K
    J Gastrointest Surg; 2014 Jan; 18(1):60-8. PubMed ID: 24101450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of doctor-pharmacist collaborative prescribing for venous thromboembolism in high risk surgical patients.
    Hale A; Merlo G; Nissen L; Coombes I; Graves N
    BMC Health Serv Res; 2018 Oct; 18(1):749. PubMed ID: 30285744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients.
    Le P; Martinez KA; Pappas MA; Rothberg MB
    J Thromb Haemost; 2017 Jun; 15(6):1132-1141. PubMed ID: 28371250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
    Mahmoudi M; Sobieraj DM
    Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
    Kotirum S; Chongmelaxme B; Chaiyakunapruk N
    J Thromb Thrombolysis; 2017 Feb; 43(2):252-262. PubMed ID: 27704332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
    Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
    Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
    Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT
    Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is extended thromboprophylaxis necessary in elective colorectal cancer surgery?
    Chandra R; Melino G; Thomas M; Lawrence MJ; Hunter RA; Moore J
    ANZ J Surg; 2013 Dec; 83(12):968-72. PubMed ID: 23802729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
    Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD004318. PubMed ID: 30916777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia.
    Torrejon Torres R; Saunders R; Ho KM
    J Orthop Surg Res; 2019 Apr; 14(1):93. PubMed ID: 30940168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
    Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD004318. PubMed ID: 30481366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of apixaban for prevention of venous thromboembolic events in patients after gynecologic cancer surgery.
    Glickman A; Brennecke A; Tayebnejad A; Matsuo K; Guntupalli SR; Sheeder J
    Gynecol Oncol; 2020 Nov; 159(2):476-482. PubMed ID: 32854972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness of graduated compression stockings for prevention of venous thromboembolism in orthopedic and abdominal surgery patients requiring extended pharmacologic thromboprophylaxis.
    Milinis K; Shalhoub J; Coupland AP; Salciccioli JD; Thapar A; Davies AH
    J Vasc Surg Venous Lymphat Disord; 2018 Nov; 6(6):766-777.e2. PubMed ID: 30126797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective.
    Trepanier M; Alhassan N; Sabapathy CA; Liberman AS; Charlebois P; Stein BL; S Feldman L; Lee L
    Dis Colon Rectum; 2019 Nov; 62(11):1381-1389. PubMed ID: 31318768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
    Yan X; Gu X; Xu Z; Lin H; Wu B
    Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
    Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
    CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.